Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2021-06-02 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-06-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 26, 2021. It announces the FDA Emergency Use Authorization for sotrovimab, a monoclonal antibody treatment for COVID-19, and includes a press release and an updated corporate presentation as exhibits. The content focuses on a significant event (EUA grant) and corporate updates rather than detailed financial results or comprehensive reports. There are no financial statements or detailed financial analysis present. The document is primarily an event announcement and includes a corporate presentation. According to the classification rules, such filings announcing events and including presentations are best classified as Regulatory Filings (RNS) because it does not fit into other specific categories like Earnings Release or Investor Presentation (the presentation is attached but the filing itself is an 8-K event report). The document length (9241 characters) is sufficient to contain substantive information but it is not a full financial report or earnings release. Therefore, the best fit is Regulatory Filings (RNS).
2021-05-27 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-25 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-25 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-25 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.